Salt, aldosterone and hypertension

Journal of Human Hypertension

Volumn 27, Issue 1, 2013, Pages 1-6

  Pimenta, E ^a   Gordon, R D ^a   Stowasser, M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

aldosterone; hypertension; salt

Indexed keywords

ALDOSTERONE; CAPTOPRIL; HYDROCHLOROTHIAZIDE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE;

ADRENALECTOMY; ALCOHOL CONSUMPTION; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANTIHYPERTENSIVE THERAPY; BODY MASS; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; ECHOCARDIOGRAPHY; GEOMETRY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE GEOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS (TOPIC); NONHUMAN; POTASSIUM EXCRETION; PRIMARY HYPERALDOSTERONISM; PROTEIN URINE LEVEL; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; REVIEW; SALT INTAKE; SODIUM APPETITE; SODIUM URINE LEVEL; TARGET ORGAN; TREATMENT DURATION;

ALDOSTERONE; ANIMALS; APPETITE; CARDIOVASCULAR DISEASES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY DISEASES; SODIUM CHLORIDE, DIETARY;

EID: 84870821187     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.27     Document Type: Review

References (43)

1. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation 2011; 123(10): 1138-1143.
2. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerova J, Richart T et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 2011; 305(17): 1777-1785.
3. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane Review). Am J Hypertens 2011; 24(8): 843-853.
4. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89(3): 1045-1050.
5. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93(9): 3266-3281.
6. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Primary aldosteronism: hypertension with a genetic basis. Lancet 1992; 340(8812): 159-161.
7. Grim CE, Weinberger MH, Higgins JT, Kramer NJ. Diagnosis of secondary forms of hypertension. A comprehensive protocol. JAMA 1977; 237(13): 1331-1335.
8. Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ et al. Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med. 1979; 90(3): 386-395.
9. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153(18): 2125-2129.
10. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009; 94(10): 3623-3630.
11. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42(2): 161-165.
12. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403-1419.
13. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16(11 Part 1): 925-930.
14. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168(11): 1159-1164.
15. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45(8): 1243-1248.
16. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168(1): 80-85.
17. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65(14): 1G-7G.
18. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25(5): 563-575.
19. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82(5): 1730-1736.
20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10): 709-717.
21. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309-1321.
22. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50(5): 911-918.
23. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95(6): 1471-1478.
24. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90(9): 5070-5076.
25. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98(4): 1063-1068.
26. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31(1 Part 2): 451-458.
27. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48(2): 232-238.
28. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295(22): 2638-2645.
29. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 h urinary sodium and potassium excretion. BMJ 1988; 297(6644): 319-328.
30. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a metaanalysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16(11): 761-770.
31. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54(3): 475-481.
32. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120(6): 893-901.
33. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141(10): 3871-3878.
34. Young MJ, Rickard AJ. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis. Mol Cell Endocrinol 2012; 350(2): 248-255.
35. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006; 69(11): 2064-2069.
36. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008; 51(2): 339-344.
37. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab 2011; 96(9): 2813-2820.
38. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 2010; 56(5): 865-870.
39. Makhanova N, Sequeira-Lopez ML, Gomez RA, Kim HS, Smithies O. Disturbed homeostasis in sodium-restricted mice heterozygous and homozygous for aldosterone synthase gene disruption. Hypertension 2006; 48(6): 1151-1159.
40. Tordoff MG, Hughes RL, Pilchak DM. Different effects of three aldosterone treatments on plasma aldosterone and salt intake. Physiol Behav 1993; 54(1): 129-134.
41. Wolf G. Effect of deoxycorticosterone on sodium appetite of intact and adrenalectomized rats. Am J Physiol 1965; 208: 1281-1285.
42. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001; 281(5): H2241-H2251.
43. Pimenta E, Gordon R, Ahmed A, Cowley D, Robson D, Kogovsek C et al. A-001 aldosterone excess stimulates salt appetite in patients with aldosterone producing adenoma. J Hypertens 29(Suppl B): e1.